Trial record 1 of 1 for:
NCT01410890
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease (PAPAYA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01410890 |
|
Recruitment Status :
Recruiting
First Posted : August 5, 2011
Last Update Posted : November 9, 2018
|
Sponsor:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
- The primary objective of this study is to characterize the pharmacokinetics of alglucosidase alfa manufactured at the 4000 L scale in patients who have a confirmed diagnosis of Pompe disease.
- A secondary objective of this study is to evaluate and explore the relationship between anti-rhGAA antibody titers and the pharmacokinetics of alglucosidase alfa.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pompe Disease (Late-Onset) Glycogen Storage Disease Type II (GSD II) | Biological: alglucosidase alfa | Phase 4 |
The total study duration per patient will be 4 to 9 weeks that consist of a screening period (from 2 days to 4 weeks), treatment visit (1 day), and a follow up call (≥30 days).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease |
| Actual Study Start Date : | November 3, 2014 |
| Estimated Primary Completion Date : | August 28, 2019 |
| Estimated Study Completion Date : | August 28, 2019 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Alglucosidase Alfa
| Arm | Intervention/treatment |
|---|---|
|
Experimental: alglucosidase alfa
alglucosidase alfa intravenous (IV) infusion of 20mg/kg body weight
|
Biological: alglucosidase alfa
Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
Other Name: Lumizyme |
Primary Outcome Measures :
- Maximum observed concentration (Cmax) [ Time Frame: Day 1 ]
- Actual sampling time to reach maximum observed concentration (Tmax) [ Time Frame: Day 1 ]
- Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (AUC last) [ Time Frame: Day 1 ]
- Area under the concentration-time curve from time 0 and extrapolated to infinite time (AUC inf) [ Time Frame: Day 1 ]
- Terminal elimination half-life (T1/2) [ Time Frame: Day 1 ]
- Total systemic clearance (CL) [ Time Frame: Day 1 ]
- Volume of distribution (Vd) [ Time Frame: Day 1 ]
Secondary Outcome Measures :
- Pharmacokinetic (PK) parameters assessed in relation to anti-rhGAA antibody titers [ Time Frame: Day 1 ]
- Pharmacokinetic (PK) parameters assessed in relation to inhibitory/neutralizing anti-rhGAA antibody titers [ Time Frame: Day 1 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
A patient must meet all of the following criteria to be eligible for this study:
- The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent.
- The patient has a confirmed GAA enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.
- Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.
- The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.
- For patients previously treated with alglucosidase alfa the patient has received alglucosidase alfa for at least 6 months.
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from this study:
- The patient is participating in another clinical study using an investigational product.
- The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01410890
Contacts
| Contact: For site information, send an email with site number to | Contact-Us@sanofi.com | ||
| Contact: Medical Information | 617-252-7832 | medinfo@genzyme.com |
Locations
| United States, Arizona | |
| Investigational Site Number 840002 | Recruiting |
| Phoenix, Arizona, United States, 85013 | |
| United States, California | |
| Investigational Site Number 840006 | Recruiting |
| Orange, California, United States, 92868 | |
| United States, Ohio | |
| Investigational Site Number 840007 | Recruiting |
| Cincinnati, Ohio, United States, 45219 | |
| United States, Utah | |
| Investigational Site Number 840005 | Recruiting |
| Salt Lake City, Utah, United States, 84108 | |
| United States, Virginia | |
| Investigational Site Number 840003 | Recruiting |
| Fairfax, Virginia, United States, 22030 | |
| Bulgaria | |
| Investigational Site Number 1028 | Recruiting |
| Sofia, Bulgaria, 1113 | |
| India | |
| Investigational Site Number 356001 | Recruiting |
| New Delhi, India, 110 029 | |
| Investigational Site Number 356002 | Recruiting |
| Vellore, India, 632004 | |
| Russian Federation | |
| Investigational Site Number 643001 | Completed |
| Moscow, Russian Federation, 125367 | |
| Investigational Site Number 643002 | Completed |
| Moscow, Russian Federation, 125412 | |
| Ukraine | |
| Investigational Site Number 804001 | Recruiting |
| Kiev, Ukraine, 01135 | |
| United Kingdom | |
| Investigational Site Number 826003 | Recruiting |
| Birmingham, United Kingdom, B4 6NH | |
| Investigational Site Number 826002 | Recruiting |
| Salford, United Kingdom, M6 8HD | |
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
| Study Director: | Medical Monitor | Genzyme, a Sanofi Company |
| Responsible Party: | Genzyme, a Sanofi Company |
| ClinicalTrials.gov Identifier: | NCT01410890 History of Changes |
| Other Study ID Numbers: |
AGLU07710 2010-022231-11 ( EudraCT Number ) MSC12790 ( Other Identifier: Sanofi ) |
| First Posted: | August 5, 2011 Key Record Dates |
| Last Update Posted: | November 9, 2018 |
| Last Verified: | November 2018 |
Additional relevant MeSH terms:
|
Glycogen Storage Disease Type II Glycogen Storage Disease Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Carbohydrate Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases |